A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma

Condition:   Multiple Myeloma Intervention:   Biological: BCMA/CD19 Dual-Target CAR-T Sponsors:   Xijing Hospital;   Gracell Biotechnology Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials